08:21 AM EDT, 07/07/2025 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Monday its board has authorized a program to repurchase up to $150 million in shares through the end of 2026.

The new program replaces a previous $150 million buyback authorized in 2024 which expired on June 30 with $65 million remaining, the biopharmaceutical company said.

Shares of the company were up 3.7% in recent premarket activity.